key: cord-0956925-vysouydj authors: Pezzati, Laura; Giacomelli, Andrea; Mileto, Davide; Conti, Federico; Gagliardi, Gloria; Rizzo, Alberto; Milazzo, Laura; Schiuma, Marco; Covizzi, Alice; Siano, Matteo; Bassoli, Cinzia; Passerini, Matteo; Piscaglia, Marco; Torre, Alessandro; Oreni, Letizia; Rizzardini, Giuliano; Galli, Massimo; Ridolfo, Anna Lisa; Antinori, Spinello title: Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: a cross-sectional study.: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine. date: 2021-05-29 journal: J Infect DOI: 10.1016/j.jinf.2021.05.029 sha: b5bcd93c7bedbbc1ad16a888d718b78c5cda212f doc_id: 956925 cord_uid: vysouydj nan Rapid lateral-flow immunochromatographic tests (RLITs) can detect IgG and/or IgM antibodies against SARS-CoV-2 proteins N and/or S in capillary blood, serum, and plasma: this point of care method has already been successfully used in population studies [4] [5] [6] [7] . Another application of RLITs could be in the qualitative determination of antibody response after SARS-CoV-2 vaccination. In Italy, the immunization campaign started on 27 th December 2020 with the priority given to health care workers (HCWs) vaccinated with BNT162b2 vaccine. BNT162b2 has been demonstrated to elicit a robust anti S antibody response in up to 95% of individuals after the second shot [3] . Although, the detection of antibodies in peripheral blood samples is the gold standard, it is expensive and needs expert personnel. These barriers could be overcome by RLITs, but studies assessing the performance of RLITs after BNT162b2 vaccine are lacking and whether they could adequately detect this response is unknown. The aim of our study was to estimate the qualitative antibody response elicited by BNT162b2 vaccine using different RLITs in a sample of vaccinated HCWs at Luigi Sacco Hospital, Milan, Italy. In this cross-sectional study, we estimated the antibody response to SARS-CoV-2 antigens (N and S proteins) using three different RLITs in a group of vaccinated HCWs. RLITs were performed between 25 th January and 16 th February 2021, 7 (±3) days after the second BNT162b2 dose. All the hospital staff was invited to participate on a voluntary basis, and everyone gave written informed consent. A questionnaire was filled to assess gender, age, and previous self- Units (BAU)/mL on peripheral blood was considered as positive [8] . To estimate vaccine response, assuming a response rate ≥95% with a 95% confidence interval and a precision of at least 5%, a minimum of 73 subjects was needed. The study was approved by University of Milan's Ethical Committee. Of the 160 HCWs included in the analysis, 110 (68.8%) were female and the median age was 41 years (Table 1) . Twenty-six (16%) reported a previous SARS-CoV-2 exposure. All subjects tested positive on anti S peripheral blood with significantly higher titers observed in subjects previously Only two subjects with no known previous SARS-CoV-2 exposure tested negative with anti-N and anti-S COVID-19 IgG/IgM rapid test cassette. Although both subjects tested positive with CLIA, they showed the lowest antibody titre in the cohort (64 BAU/mL and 253 BAU/mL). In addition, both subjects reported autoimmune disorders: in one case atopic dermatitis treated with janus kinase inhibitor and in the other systemic lupus erythematosus treated with hydroxychloroquine. The observed higher titers in subjects with a previous SARS-CoV-2 exposure when compared to those unexposed before vaccination was in line with previous observations suggesting that just one single dose of BNT162b2 vaccine could be sufficient to elicit an adequate antibody titre [9] . Our study presents some limitations. First, not all subjects had an available anti-N titre to systematically ascertain SARS-CoV-2 exposure before vaccination and consequently asymptomatic infections could not be definitely ruled out. Second, the study population is a convenience sample of HCWs not representative of the vaccinated general population. Third, a single serological determination was performed, thus not allowing a longitudinal assessment of test performance overtime. In the end, the absence of vaccine non-responders (with a negative antibody titre) does not allow the assessment of different tests' specificity. In conclusion, RLITs could be considered for a qualitative assessment of BNT162b2 vaccine antibody response. RLITs could serve as a tool for a rapid point of care evaluation in people at risk of non-response (i.e. those exposed to immunosuppressant agents). In this population a negative result should be further evaluated by means of CLIA. Is COVID-19 severity associated with antispike antibody duration? Data from the ARCOVID prospective observational study Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study LIAISON® SARS-CoV-2 S1/S2 IgG data sheet Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine We thank all the hospital staff voluntary participating in the present study.